All In Biotech

Drug Trial Radar · NCT00612742

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,656 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,656

Actual

Start

Jan 2008

Primary completion

Oct 2012

Study completion Dec 2012

Sponsor

Lead sponsor
BioSante PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 12, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD in postmenopausal women with at least two points of cardiovascular risk and clinical diagnosis of Hypoactive Sexual Desire Disorder (HSDD).

Conditions

  • Hypoactive Sexual Desire Disorder

Interventions

  • testosterone gelDrug

    once daily transdermal testosterone gel, 300 mcg

  • placebo gelDrug

    once daily transdermal placebo gel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of adjudicated, predefined cardiovascular events in LibiGel-treated subjects compared to that of placebo-treated subjects.Time frame: 2011 primary outcome analysis for NDA submission

Locations

149 sites in 2 countries. Site status is shown where the registry gives one.

  • BioSante Site #215

    Birmingham, Alabama

  • BioSante Site 185

    Birmingham, Alabama

  • BioSante Site 095

    Hoover, Alabama

  • BioSante Site #014

    Huntsville, Alabama

  • BioSante Site 196

    Huntsville, Alabama

  • BioSante Site 146

    Mobile, Alabama

  • BioSante Site 171

    Chandler, Arizona

  • BioSante Site 145

    Glendale, Arizona

  • BioSante Site 027

    Glendale, Arizona

  • BioSante Site 121

    Phoenix, Arizona

  • BioSante Site 137

    Tucson, Arizona

  • BioSante Site 040

    Tucson, Arizona

  • BioSante Site 052

    Hot Springs, Arkansas

  • BioSante Site 100

    Jonesboro, Arkansas

  • BioSante Site #060

    Little Rock, Arkansas

  • BioSante Site 155

    Little Rock, Arkansas

  • BioSante Site 011

    Los Angeles, California

  • BioSante Site 094

    Palm Springs, California

  • BioSante Site 043

    Roseville, California

  • BioSante Site 162

    Sacramento, California

  • BioSante Site 025

    Sacramento, California

  • BioSante Site 112

    San Diego, California

  • BioSante Site 008

    San Diego, California

  • BioSante Site #070

    San Diego, California

  • BioSante Site 205

    San Diego, California

  • BioSante Site #192

    San Diego, California

  • BioSante Site 159

    Walnut Creek, California

  • BioSante Site 007

    Denver, Colorado

  • BioSante Site 216

    Denver, Colorado

  • BioSante Site 026

    Lakewood, Colorado

  • BioSante Site 166

    Farmington, Connecticut

  • BioSante Site 103

    Hartford, Connecticut

  • BioSante Site 132

    New Britain, Connecticut

  • BioSante Site 151

    New London, Connecticut

  • BioSante Site 036

    Ridgefield, Connecticut

  • BioSante Site 013

    Washington D.C., District of Columbia

  • BioSante Site 118

    Aventura, Florida

  • BioSante Site 139

    Crystal River, Florida

  • BioSante Site 143

    Jacksonville, Florida

  • BioSante Site 180

    Melbourne, Florida

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.